Edition:
United Kingdom

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

4.11USD
14 Dec 2017
Change (% chg)

$-0.16 (-3.75%)
Prev Close
$4.27
Open
$4.30
Day's High
$4.45
Day's Low
$4.10
Volume
18,709
Avg. Vol
36,796
52-wk High
$21.86
52-wk Low
$3.60

Chart for

About

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80... (more)

Overall

Beta: 0.47
Market Cap(Mil.): $94.37
Shares Outstanding(Mil.): 17.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.16 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Apollo Endosurgery Inc Files For Stock Shelf Of Upto $50 Million - SEC Filing ‍​

* APOLLO ENDOSURGERY INC FILES FOR STOCK SHELF OF UPTO $50 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2AONduG) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Dec 2017

BRIEF-Apollo Endosurgery Receives FDA Clearance For Overstitch Sx Endoscopic Suturing System

* APOLLO ENDOSURGERY RECEIVES FDA CLEARANCE FOR OVERSTITCH™ SX ENDOSCOPIC SUTURING SYSTEM

27 Nov 2017

BRIEF-David Pacitti joins Apollo Endosurgery board of directors

* David C. Pacitti joins Apollo Endosurgery board of directors

16 Nov 2017

BRIEF-Apollo Endosurgery reports qtrly loss per share $‍0.32​

* Apollo Endosurgery Inc - qtrly loss per share $‍0.32​ Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Apollo endosurgery announces CE mark approval for the Orbera365™ managed weight loss system,

* Apollo Endosurgery announces CE mark approval for the Orbera365™ managed weight loss system, expanding the indwell period from 6 months to 12 months with the gastric balloon category leader

30 Aug 2017

BRIEF-Stonepine Capital Management Llc reports 13.7 percent passive stake in Apollo Endosurgery Inc

* Stonepine Capital Management Llc reports 13.7 percent passive stake in Apollo Endosurgery Inc as of August 11, 2017 - SEC filing‍​ Source text: (http://bit.ly/2xbQJty) Further company coverage:

18 Aug 2017

BRIEF-Novo Holdings A/S reports 3.9 pct stake in Apollo Endosurgery as on Aug 14

* Novo Holdings A/S reports 3.9 percent stake in Apollo Endosurgery Inc as on August 14, 2017 - SEC filing‍​

16 Aug 2017

BRIEF-Apollo Endosurgery Q2 revenue $17.1 mln

* Apollo Endosurgery - total endo-bariatric revenues were $9.5 million for three months ended june 30, 2017, an increase of 13.0% compared to q2 of 2016

01 Aug 2017

BRIEF-Apollo Endosurgery files amended S-1 registration statement

* Files amended S-1 registration statement, sees offering of 3.5 million shares of its common stock - SEC filing

12 Jul 2017

Earnings vs. Estimates